natgillin/translations-raw huggingface dataset:
Efficacy of Econor was compared with the efficacy of an oral treatment with other antibiotics approved in the EU for the indication or with animals that did not receive any medication.
Učinkovitost zdravila Econor so primerjali z učinkovitostjo peroralnega načina zdravljenja z drugimi antibiotiki, ki so odobreni v EU za zadevno indikacijo, ali z rezultati pri živalih, ki niso prejemale zdravila.
Efficacy of enzalutamide was established in two randomized placebo-controlled multicentre phase 3 clinical studies [CRPC2 (AFFIRM), MDV3100-03 (PREVAIL)] of patients with progressive metastatic prostate cancer who had failed androgen deprivation therapy [luteinising hormone-releasing hormone (LHRH) analogue or after bilateral orchiectomy].
Učinkovitost enzalutamida so ugotavljali v dveh randomiziranih, s placebom kontroliranih multicentričnih kliničnih študijah 3. faze [CRPC2 (AFFIRM), MDV3100-03 (PREVAIL)] pri bolnikih s progresivnim metastatskim rakom prostate, pri katerih zdravljenje z odtegnitvijo androgena ni bilo uspešno [analog luteinizirajočega, hormon sproščajočega hormona (LHRH, luteinising hormone-releasing hormone) ali po obojestranski orhidektomiji].
Efficacy of Ilaris in a subset of young adult SJIA patients aged 16 to 20 years was consistent with the efficacy observed for patients less than 16 years of age.
V podskupini mladih odraslih bolnikov s SJIA, ki so bili stari od 16 do 20 let, je bila učinkovitost zdravila Ilaris podobna kot pri tistih bolnikih, ki so bili stari manj kot 16 let.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje, da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana, v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – NZ populacija in histološke podskupine
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabin u skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – ITT populacija in histološke poskupine
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri prvem izboru nedrobnoceličnega karcinoma pljuč – NZ populacija in histološke podskupine
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prve izbire nedrobnoceličnega pljučnega raka – NZ populacija in histološke podskupine
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – ITT populacija in histološke poskupine
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – NZ populacija in histološke podskupine
Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma
Učinkovitost pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – NZ populacija in histološke podskupine
Efficacy of pemetrexed plus cisplatin vs.cisplatin in malignant pleural mesothelioma
Učinkovitost pemetrekseda skupaj s cisplatinom v primerjavi s cisplatinom pri malignem plevralnem mezoteliomu
Efficacy of pemetrexed vs docetaxel in NSCLC - ITT population
Učinkovitost pemetrekseda v primerjavi z docetakselom pri NSCLC - ITT populacija
Efficacy of pemetrexed vs docetaxel in NSCLC - ITT population
Učinkovitost pemetrekseda v primerjavi z docetakselom pri NSCLC - populacija NZ
Efficacy of pemetrexed vs. docetaxel in NSCLC - ITT population
Učinkovitost pemetrekseda v primerjavi z docetakselom pri NSCLC - Populacija NZ
Efficacy of PREZISTA 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-naïve patients
Učinkovitost zdravila PREZISTA 800 mg enkrat na dan s 100 mg ritonavirja enkrat na dan, pri bolnikih, ki še nimajo izkušenj z ART
Efficacy of PREZISTA 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-naïve patients
Učinkovitost zdravila PREZISTA 800 mg enkrat na dan skupaj s 100 mg ritonavirja enkrat na dan, pri bolnikih, ki nimajo izkušenj z ART
Efficacy of sildenafil should be closely monitored in patients using concomitant potent CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, St John’s wort and rifampicine.
Učinkovitost sildenafila je treba natančno nadzirati pri bolnikih, ki sočasno uporabljajo močne induktorje CYP3A4, npr. karbamazepin, fenitoin, fenobarbital, šentjanževko ali rifampicin.
Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.
Učinkovitosti izdelka pri mačkah s tumorozno obliko okužbe s FeLV, mačkah okuženih s FeLV ali v primeru sočasne okužebe s FIV v terminalnem stadiju niso testirali.
Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.
Učinkovitosti izdelka pri mačkah s tumorozno obliko okužbe s FeLV, mačkah okuženih s FeLVali v primeru sočasne okužbe s FIV v terminalnem stadiju niso testirali.
Efficacy of zonisamide as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine prolonged release (PR) in 583 adult subjects with newly diagnosed partial seizures with or without secondary generalised tonic-clonic seizures.
Učinkovitost zonisamida kot monoterapije so dokazali v dvojno slepi primerjavi neinferiornosti z vzporednimi skupinami s karbamazepinom s podaljšanim sproščanjem pri 583 odraslih osebah z na novo diagnosticiranimi parcialnimi epileptičnimi napadi s sekundarno generaliziranimi tonično- klonični napadi ali brez njih.
Efficacy of zonisamide as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine prolonged release (PR) in 583 adult subjects with newly diagnosed partial seizures with or without secondary generalised tonic-clonic seizures.
Učinkovitost zonisamida kot monoterapije so dokazali v dvojno slepi primerjavi enakovrednosti z vzporednimi skupinami s karbamazepinom s podaljšanim sproščanjem pri 583 odraslih osebah z na novo diagnosticiranimi parcialnimi epileptičnimi napadi s sekundarnimi generaliziranimi tonično- kloničnimi napadi ali brez njih.
Efficacy Outcome at Week 48 in CNA30021 by baseline HIV-1 RNA and CD4 Categories (ITTe TLOVR ART naïve subjects).
Izid učinkovitosti 48. teden v CNA30021 po izhodiščnih kategorijah HIV-1 RNA in CD4 (ZNZ-I TLOVR, preiskovanci, še nezdravljeni s protiretrovirusnimi zdravili).
Efficacy Outcome at Weeks 48 and 240
Izid učinkovitosti v 48. in 240. tednu zdravljenja
Efficacy Outcome at Weeks 48 and 240
Rezultati učinkovitosti po 48 in 240 tednih zdravljenja
Efficacy Outcome at Weeks 48 and 96
Izid učinkovitosti v 48. in 96. tednu zdravljenja
Efficacy Outcome at Weeks 48 and 96
Rezultati učinkovitosti po 48 in 96 tednih zdravljenja
Efficacy Outcomes
Izid učinkovitosti
Efficacy parameter
Parametri učinkovitosti
Efficacy Parameter1
Parameter učinkovitosti1
Efficacy parameters
Parametri učinkovitosti
Efficacy results
Rezultati glede učinkovitosti
Efficacy results are presented in Table 4.
Rezultati učinkovitosti so prikazani v preglednici 4.
Efficacy results are presented in Table 5 and Figure 1.
Rezultati učinkovitosti so predstavljeni v tabeli 5 in na sliki 1.
Efficacy results are presented in Table 5.
Rezultati o učinkovitosti so predstavljeni v preglednici 5.
Efficacy results are presented in Table 5.
Rezultati učinkovitosti so predstavljeni v preglednici 5.
Efficacy results are presented in Tables 8 and 9.
Rezultati učinkovitosti so predstavljeni v preglednici 8 in preglednici 9.
Efficacy results are presented in the table below:
Rezultate učinkovitosti povzema spodnja tabela:
Efficacy results are reported in Table 7.
Rezultati učinkovitosti so predstavljeni v preglednici 7.
Efficacy results are shown in Table 10.
Rezultati učinkovitosti so prikazani v Tabeli 10.
Efficacy results are shown in Table 12 and Figures 4 and 5.
Rezultati učinkovitosti so prikazani v Tabeli 12 in na Slikah 4 in 5.
Efficacy results are shown in Table 13.
Rezultati učinkovitosti so prikazani v Tabeli 13.
Efficacy results are shown in Table 7.
Rezultati učinkovitosti so prikazani v preglednici 7.
Efficacy results are shown in Table 9.
Rezultati učinkovitosti so prikazani v preglednici 9.
Efficacy results are summarised in Tables 5 and 6.
Rezultati učinkovitosti so povzeti v preglednicah 5 in 6.
Efficacy results are summarized in Table 7, Table 8 and Table 9.
Rezultati učinkovitosti so povzeti v preglednici 7, 8 in 9.
Efficacy results are summarized in Table 8 and in Figures 1-3.
Rezultate učinkovitosti povzemajo preglednica 8 in slike od 1 do 3.
Efficacy results are summarized in the following table.
Rezultate o učinkovitosti povzema naslednja tabela:
Efficacy results are summarized in the following table:
Rezultate učinkovitosti povzema spodnja tabela:
Efficacy results for a more stringent subgroup limited to current users of ULT (N=62) are presented in Table 4.
Rezultati učinkovitosti za ožjo podskupino bolnikov, ki so tedaj uporabljali zdravila za zmanjševanje količine urata, (N=62), so prikazani v preglednici 4.
Efficacy Results for GEMINI II and III Studies at Week 6 and Week 10
Rezultati učinkovitosti v 6. tednu in 10. tednu v študijah GEMINI II in III
Efficacy Results for GEMINI II at Week 52
Rezultati učinkovitosti v 52. tednu v študiji GEMINI II
Efficacy results for study 006 on a subset of 614 patients who had been enrolled for at least 48 weeks are found in Table 2.
Rezultate učinkovitosti študije 006 pri podskupini 614 bolnikov, vključenih vsaj 48 tednov, prikazuje preglednica 3.
Efficacy results for Study CLL3001 are shown in Table 7.
Rezultati učinkovitosti za študijo CCL3001 so prikazani v preglednici 7.
Efficacy results for Study MCL3001 are shown in Table 3 and the Kaplan-Meier curve for PFS in Figure 1.
Rezultati učinkovitosti za študijo MCL3001 so prikazani v preglednici 3, slika1 pa prikazuje Kaplan- Meierjevo krivuljo za PFS.
Efficacy results for Study PCYC-1112-CA are shown in Table 5.
V preglednici 5 so prikazani rezultati učinkovitosti v študiji PCYC-1112-CA.
Efficacy results for Study PCYC-1115-CA are shown in Table 4 and the Kaplan-Meier curves for PFS and OS are shown in Figures 2 and 3, respectively.
Rezultati učinkovitosti v študiji PCYC-1115-CA so prikazani v preglednici 4, sliki 2 in 3 pa prikazujeta Kaplan-Meierjevi krivulji za PFS in OS.
Efficacy results for the CONFIRM study are summarized in Table 2.
Rezultati študije CONFIRM so predstavljeni v preglednici 2.
Efficacy results from a Phase 2 study in patients with CF who are homozygous for the F508del mutation in the CFTR gene showed no statistically significant difference in FEV1 over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1).
Rezultati učinkovitosti iz študije faze 2 pri bolnikih s CF, ki so homozigotni za mutacijo F508del na genu CFTR, niso pokazali statistično značilne razlike v FEV1 (forsirani ekspiracijski volumen, izdihnjen v prvi sekundi) vseh 16 tednov zdravljenja z ivakaftorjem v primerjavi s placebom (glejte poglavje 5.1).
Efficacy results from AURA studies
Rezultati učinkovitosti v študijah AURA
Efficacy results from AURA studies as well as pooled analysis (AURAex and AURA2) are summarized in Table 3.
Rezultati učinkovitosti iz študij AURA in združena analiza (AURAex in AURA2) so povzeti v preglednici 3.
Efficacy Results from Phase III NeuroBloc Studies
Rezultati učinkovitosti zdravila NeuroBloc v študijah III faze
Efficacy results from randomised Phase 3 Study 1007 (full analysis population) in patients with previously treated ALK-positive advanced NSCLC
Rezultati učinkovitosti iz randomizirane študije 3. faze, Študije 1007 (celotna populacija za analizo) pri bolnikih s predhodno zdravljenim ALK-pozitivnim napredovalim NSCLC
Efficacy results from Study ET743-SAR-3007
Rezultati učinkovitosti iz študije ET743-SAR-3007
Efficacy results from the primary analysis and a post-hoc analysis with 6-months additional follow up are summarised in Table 8.
Rezultati učinkovitosti iz primarne analize in post hoc analize po dodatnem 6-mesečnem spremljanju so povzeti v preglednici 8.
Efficacy results in patients ≥ 18 years of age with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL)
Rezultati učinkovitosti pri bolnikih, starih ≥ 18 let, ki so imeli recidivno ali refraktarno akutno limfoblastno levkemijo (ALL) predhodniških celic B z negativnim Philadelphia kromosomom
Efficacy results in the follicular lymphoma population are shown in Table 9.
Rezultate učinkovitosti v populaciji s folikularnim limfomom prikazuje preglednica 9.
Efficacy results in the subgroup of patients corresponding to the approved indication are described below.
Rezultati o učinkovitosti pri podskupini bolnikov, zajeti v odobreni indikaciji, so opisani spodaj.
Efficacy results were also assessed by an Independent Review Committee (IRC) demonstrating an ORR of 83%, with a 11% VGPR rate and a 51% PR rate.
Podatke o učinkovitosti je ovrednotila neodvisna komisija za pregled podatkov (IRC - Independent Review Committee) in ugotovila, da je ORR znašal 83%, pri čemer je bilo bolnikov z VGPR 11%, bolnikov z delnim odgovorom pa 51%.
Efficacy Results: FAST-3; Controlled Phase -- ITT population
Rezultati za učinkovitost: FAST-3; nadzorovana faza – populacija, ki so jo nameravali zdraviti (ITT)
Efficacy studies were also performed in ferrets.
Študije učinkovitosti so bile izvedene tudi pri belih dihurjih.
Efficacy study (NIH sponsored)
Študija učinkovitosti (sponzorirana s strani NIH)
Efficacy tended to be lower in patients positive for antibodies to ustekinumab; however, antibody positivity did not preclude a clinical response.
Pri bolnikih s pozitivnim izvidom na protitelesa proti ustekinumabu je bila učinkovitost zdravljenja manjša, vendar pozitiven izvid na protitelesa ne pomeni, da se bolnik ni odzval na zdravljenje.
Efficacy trials in the 2- to 5-year-old population have not been conducted.
Preskušanj učinkovitosti pri populaciji otrok, starih od 2 do 5 let, niso opravili.
Efficacy versus amiodarone (AVRO):
Učinkovitost v primerjavi z amiodaronom (AVRO):
Efficacy versus placebo was significant across a range of subgroups which included patients separated by the following baseline characteristics: age (all subgroups up to age 65 years); body weight (up to 80 kg) and oophorectomy (up to 15 years ago).
Učinkovitost v primerjavi s placebom je bila pomembna v obsegu podskupin, v katerih so bile bolnice, ki so jih ločili glede na naslednje značilnosti: starost (vse podskupine do starosti 65 let), telesna masa (do 80 kg) in ooforektomija (do pred 15 leti).
Efficacy was also demonstrated for the two secondary endpoints in the per protocol population.
Učinkovitost je bila dokazana tudi za dva sekundarna opazovana dogodka v populaciji po protokolu.
Efficacy was also evaluated by calculation of treatment response (defined as decrease in PANSS Total Score ≥ 30%) as a secondary endpoint.
Dodatni cilj študije je bila ocena odziva na zdravljenje (opredeljen kot zmanjšanje skupnega rezultata PANSS za ≥ 30%).
Efficacy was also observed in more severely depressed patients (baseline HAM-D  25) in all positive placebo-controlled trials.
Učinkovitost so dokazali tudi pri bolnikih s hujšo depresijo (izhodiščni seštevek po Hamiltonovi ocenjevalni lestvici za depresijo ≥ 25) v vseh pozitivnih s placebom nadzorovanih preskušanjih.
Efficacy was assessed in 6 placebo-controlled, double-blind, randomized Phase II and III clinical studies evaluating 28,413 individuals (20,541 girls and women 16 through 26 years of age, 4,055 boys and men 16 through 26 years of age, 3,817 women 24 through 45 years of age).
Učinkovitost so ovrednotili v 6 dvojno slepih, s placebom nadzorovanih, randomiziranih kliničnih študijah faze II in III, v katerih so ocenili 28.413 oseb (20.541 deklic in žensk, starih od 16 do 26 let,
Efficacy was based on evaluation of the composite measure: complete response (defined as no emetic episodes and no use of rescue therapy) primarily during Cycle 1.
Učinkovitost zdravljenja je temeljila na naslednjem sestavljenem merilu: popoln odziv (opredeljen kot odsotnost bruhanja in brez rešilnega zdravljenja) primarno v 1. ciklusu.
Efficacy was demonstrated if non-inferiority to risedronate was shown sequentially with respect to the percentage change in lumbar spine BMD at 12 months relative to baseline in the treatment and prevention subpopulations, respectively.
Učinkovitost je bila dokazana, če se je pokazalo, da zoledronska kislina ni bila slabša od risedronata glede odstotne spremembe mineralne gostote kosti ledvene hrbtenice po 12 mesecih v primerjavi z izhodiščno vrednostjo, in sicer posebej v podskupini za zdravljenje in posebej v podskupini za preprečevanje osteoporoze.
Efficacy was determined by the subject’s response to therapy in terms of responder and absolute improvement in the time spent “off”.
Učinkovitost je bila določena glede na bolnikov odziv na zdravljenje, izražen kot izboljšanje stopnje odziva bolnika in absolutnega časa v fazi »izklop«.
Efficacy was determined by the subject’s response to therapy in terms of responder and absolute points improvement in the scores of ADL and Motor Examination combined (UPDRS part II+III).
Učinkovitost je bila določena glede na bolnikov odziv na zdravljenje, izražen kot izboljšanje stopnje odziva bolnika in absolutnega števila točk skupnega rezultata ADL in motoričnega pregleda lestvice UPDRS (II. + III. del).
Efficacy was determined by the subject’s response to therapy in terms of responder and absolute points improvement in the scores of ADL and Motor Examination combined (UPDRS part II+III).
Učinkovitost je bila določena glede na bolnikov odziv na zdravljenje, izražen kot izboljšanje stopnje odziva bolnika in absolutnega števila točk skupnega rezultata ADL in motoričnega pregleda lestvice UPDRS II. + III. del).
Efficacy was established by the use of ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance-based measure of cognition) and the ADCS-IADL (Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living) assessing instrumental activities which include maintaining finances, meal preparation, shopping, ability to orient oneself to surroundings, ability to be left unattended.
Učinkovitost so ugotavljali z metodama ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti) in ADCS-IADL (Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living, ocena zahtevnejših vsakodnevnih aktivnosti), s katero je mogoče oceniti bolnikove sposobnosti izvajanja aktivnosti, med katere sodijo ukvarjanje z denarnimi zadevami, pripravljanje obrokov, nakupovanje, zmožnosti orientacije v okolju in samostojnost do te mere, da je bolnika mogoče pustiti brez nadzora.
Efficacy was established in two randomised placebo-controlled multicentre phase 3 clinical studies (studies 301 and 302) of patients with metastatic castration resistant prostate cancer.
Učinkovitost so ugotavljali v dveh randomiziranih, s placebom nadzorovanih, multicentričnih kliničnih študijah faze III (študiji 301 in 302) pri bolnikih z metastatskim rakom prostate odpornim na kastracijo.
Efficacy was evaluated using PANSS.
Učinek so ocenili z lestvico PANSS.
Efficacy was maintained in all subjects regardless of seropositivity status for any vaccine HPV type through the end of the study (up to 67 months postdose 3; median follow-up duration of 43 months postdose 3).
Učinkovitost se je ohranila do konca študije (do 67 mesecev po 3. odmerku; mediani čas spremljanja 43 mesecev po 3. odmerku) pri vseh preiskovancih, ne glede na stanje seropozitivnosti za kateri koli tip HPV.
Efficacy was maintained over the full 24-hour dosing period with once daily administration.
Pri odmerjanju enkrat na dan se je učinkovitost ohranila celotno 24-urno odmerno obdobje.
Efficacy was measured starting after the Month 7 visit.
Učinkovitost so začeli meriti ob obisku v 7. mesecu.
Efficacy was not assessed in this study.
Učinkovitosti v tej študiji niso ocenjevali.
Efficacy was observed both for patients with newly diagnosed disease and for patients with relapsing disease (Table 15).
Učinkovitost so ugotovili tako pri bolnikih z novoodkrito boleznijo kot pri bolnikih s ponovitvijo bolezni (preglednica 15).
Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with vedolizumab (see section 4.8).
Pri ponovni uvedbi zdravljenja je bila učinkovitost vedolizumaba znova dosežena, brez očitnega povečanja pogostnosti neželenih učinkov ali reakcij, povezanih z infundiranjem (glejte poglavje 4.8).
Efficacy was studied in a total of 390 haemodynamically stable adult patients with short duration atrial fibrillation including patients with hypertension (40.5%), ischaemic heart disease (12.8%), valvular heart disease (9.2%) and CHF (10.8%).
Učinkovitost so raziskali pri skupaj 390 hemodinamsko stabilnih odraslih bolnikih s kratkotrajno atrijsko fibrilacijo; med njimi so bili bolniki s hipertenzijo (40,5 %), ishemično boleznijo srca (12,8 %), boleznijo srčnih zaklopk (9,2 %) in kongestivnim srčnim popuščanjem (10,8 %).